Lead optimization of a long non-coding RNA (lncrna) as a potential lipid- and glucose-lowering therapeutic
Ended Awarded Last action
- Contract number
- 75N91025F00019
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $921,875
Award facts
- Contract value 100% obligated
- $921,875.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
This is a $921,875 cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for the "Lead Optimization of a Long Non-Coding RNA (LncRNA) as a Potential Lipid- and Glucose-Lowering Therapeutic." There is no set-aside designation for this contract. Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) contractor for the NCI, providing comprehensive biomedical research and facilities support services. This contract supports critical scientific research across multiple disease areas, including cancer, HIV/AIDS, influenza, COVID-19, and gene therapy. The parent company, Leidos Holdings, Inc., is a prominent global technology and engineering solutions provider that delivers services across various federal government sectors.
Quick answers
Who was awarded contract 75N91025F00019?
75N91025F00019 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2025.
How much is contract 75N91025F00019 worth?
The government has obligated $921,875 on 75N91025F00019.
Is contract 75N91025F00019 an order under another contract?
Yes. 75N91025F00019 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91025F00019 competed?
The extent of competition for 75N91025F00019 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award